Financials·Property & Casualty Insurance·$3.7B
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $1.34 | N/A | +86.89% |
| Revenue | N/A | N/A | N/A |
management commentary, guidance changes, and full analysis available with Pro.
| EPS | $1.34 | N/A | +86.89% |
| Revenue | N/A | N/A | N/A |
Tone: Cautiously Optimistic
Overall, management conveyed a cautiously optimistic outlook, emphasizing strong EPS results despite not providing specific revenue guidance.
Management expressed satisfaction with the EPS performance.
They noted that while there are challenges ahead, they remain focused on strategic initiatives.
The strong EPS performance of $1.34, significantly above expectations, contributed to a positive stock reaction, with shares rising 2.03%. This suggests that investors are encouraged by the company's ability to exceed earnings expectations, even in the absence of revenue figures or specific guidance. The management's cautious optimism may indicate a focus on navigating future challenges while maintaining profitability.
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
ALNYLAM PHARMACEUTIC
May 6, 2013